Lumen Technologies Quote - L1MN34 | ADVFN

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
Brazil
BOV
Lumen Technologies Inc (L1MN34) Share Price

Lumen Technologies Inc (L1MN34)

36.59

-1.27

(-3.35%)

Closed December 17 2:55PM

Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Current Price

36.11

Bid

36.00

Ask

38.68

Volume

4,504

36.52 Day's Range 37.90

5.47 52 Week Range 59.45

Market Cap

Previous Close

37.86

Open

37.86

Last Trade

Last Trade Time

Financial Volume

R$ 165,612

VWAP

36.77

Average Volume (3m)

15,047

Shares Outstanding

1,008,899,000

Dividend Yield

-

PE Ratio

-1.08

Earnings Per Share (EPS)

-10.21

Revenue

14.56B

Net Profit

-10.3B

Sector

Phone Comm Ex Radiotelephone

Industry

Phone Comm Ex Radiotelephone

Website

www.lumen.com

Headquarters

Baton Rouge, Louisiana, USA

Founded

-

Lumen Technologies Inc is listed in the Phone Comm Ex Radiotelephone sector of the Brazil Bovespa Exchange with ticker L1MN34. The last closing price for Lumen Technologies was R$37.86. Over the last year, Lumen Technologies shares have traded in a share price range of R$ 5.47 to R$ 59.45.

Lumen Technologies currently has 1,008,899,000 shares outstanding. The market capitalization of Lumen Technologies is R$38.20 billion. Lumen Technologies has a price to earnings ratio (PE ratio) of -1.08.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-3.41	-8.62854251012	39.52	40.29	36.11	4473	38.87872026	DR
4	-11.34	-23.8988408851	47.45	48.1	36.11	13272	43.34154559	DR
12	-3.79	-9.49874686717	39.9	59.45	33.45	15047	46.2874448	DR
26	29.68	461.586314152	6.43	59.45	5.47	12639	36.24915991	DR
52	27.22	306.186726659	8.89	59.45	5.47	7996	30.84080747	DR
156	-36.2	-50.0622320564	72.31	78	4.84	3645	26.60884942	DR
260	-22.27	-38.1466255567	58.38	87.88	4.84	2954	28.61088161	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ATED3Atom Educacao E Editora S.A.	R$ 2.05 (39.46%)	267.1k
AGXY3Agrogalaxy Participacoes SA	R$ 0.50 (25.00%)	4.74M
DOTZ3Dotz S.A.	R$ 3.20 (18.96%)	68.4k
DASA11Diagnosticos da America S.A	R$ 1.08 (13.68%)	100
IFCM3Infracommerce Caxaas S.A.	R$ 0.09 (12.50%)	9.38M
COCE11Cia Energetica Ceara Coelce	R$ 0.39 (-35.00%)	11.7k
CRPG3TronoxPigmentos do Brasil S.A.	R$ 21.15 (-20.19%)	1.5k
QUAL3Qualicorp Consultoria e Corretora de Seguros S.A.	R$ 1.79 (-17.51%)	11.66M
EPAR3Embpar Participacoes S.A.	R$ 5.65 (-15.67%)	44.5k
AZEV3Azevedo Travassos Sa	R$ 1.07 (-13.71%)	1.29M
HAPV3Hapvida Participacoes Investimento SA	R$ 2.28 (-11.28%)	313.56M
COGN3CognaEducacao SA	R$ 1.09 (1.87%)	80.64M
BBDC4Bco Bradesco Sa	R$ 11.99 (0.756303%)	66.96M
ITSA4Itausa Investimentos Itau SA	R$ 9.04 (0.110742%)	52.07M
ITUB4Itau Unibanco Holding SA	R$ 31.88 (0.536108%)	40.11M

JMoneyHoops

JMoneyHoops 4 minutes ago

Verified profile! https://x.com/jmoney_hoops/status/1869205515588501520?s=46&t=EuLw-SVIgNfV5yGP5vc4tQ

dstock07734

dstock07734 4 minutes ago

KILLAZILLA

KILLAZILLA 5 minutes ago

DILUTION IS THE MAIN EYESORE....

WITHOUT SUBSTANTIAL REVENUE IT'S A POS DILUTION SCAM......

gitreal

gitreal 5 minutes ago

...where would our country be without folks daring to dream?

Pretty sad that you can't tell the difference between a grifting penny stock CEO and a legit startup entrepreneur. Or, even worse, you do know the difference and you are pretending, just to help promote the scam. I think i

flipper44

flipper44 6 minutes ago

Those people know we can still see them, right?

awesomed007

awesomed007 6 minutes ago

If it was selling on heavy volume, that would be a concern but very light volume during end of year portfolio rebalancing, tax harvesting happening, nah, just a few fools selling.

awesomed007

awesomed007 6 minutes ago

If it was selling on heavy volume, that would be a concern but very light volume during end of year portfolio rebalancing, tax harvesting happening, nah, just a few fools selling.

Eatatjoes

Eatatjoes 6 minutes ago

Paul Malec of Deer Park, NY

fuagf

fuagf 7 minutes ago

Yeps, yeps and yeps. Good ones.

NoMoDo

NoMoDo 7 minutes ago

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175527881 Meeting announced for TODAY

Better yet. Read this closely:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175530469
Ybyra agreed to purchase a company in France. Giving Dividends.

manibiotech

manibiotech 7 minutes ago

Well if you read the link you posted yourself , they are tracking in almost every other country on the planet . Please see the table . They are giving projected global scope of what is going on
I have no problem with you posting that link every hour of that pleases you

1vman

1vman 8 minutes ago

*****🚽UBQU🚽 Kevin Lamb is the typical OTC CEO , pocketing money while share holders lose amost all their investment

So much for forbes and da T0P 10 Health innovators wow!

🤔HUZZAH ENOUGH SAID !!!🤔

janice shell

janice shell 8 minutes ago

First of all, Syria is not a big oil producer. So it's a stupid idea. Trump has put it forward because he thinks everything should be his.

And because he's a moron.

https://investorshub.advfn.com/uimage/uploads/2024/12/17/oage%5BJPEG_image.jpeg

I must so

HappyAlways

HappyAlways 9 minutes ago

I am, as a Fannie shareholder, against any government action to dilute Fannie shareholders' interest. (1) The PSPA loan is no longer valid, given the NWS payments are way over the original 10% interest payments by $310B. (2) Any attempt to exercise the free warrant will be met with lawsuits, given t

TheDane

TheDane 9 minutes ago

Not only did it hold but it’s on the way back up.

OnTrack444

OnTrack444 9 minutes ago

Might see a dime after the RS!

If you think a 30B OS OTC stock is going to run from .0011 to .10 you're smoking something pretty whacky!! Find a low OS stock with catalysts in place and it's entirely possible but not this one my friend!!! GLTY

manibiotech

manibiotech 11 minutes ago

Interesting for sure but not conclusive which he repeat every day

But there are other things mentioned in that paragraph besides "Neuroscience" ( not Neuro-oncology). And there are other categories of vaccines in development even in neuroscience

FACT-MASTER

FACT-MASTER 12 minutes ago

Pivotal Study Design.

Through a meeting with the FDA, the Company obtained feedback on the potential registrational pathway following the Phase 1 ALLOHA trial. Based on this feedback, the Company believes that for a registrational trial: (1) the following proposed patient population i

arizona1

arizona1 12 minutes ago

Never trumpers are hilarious and brilliant too.

jimr1717

jimr1717 13 minutes ago

“ which now includes 17 issued U.S. patents and 84 pending”

It has taken them from $90,000 to $2 bucks in share price to get 17 of 101 patents.

There will be people that might need a million dollar share price to brake even by then.

This Fake it sham is

NoMoDo

NoMoDo 14 minutes ago

If we don't see a dime, I will be shocked.

Slyhunter

Slyhunter 14 minutes ago

I did Uber, when it was worth doing. Made, sometimes $300 a day at the b3e3ginning when they first started in my county, It was disastrous to not get out of the car and inspect the backseat to insure it was clean between fares, especially when driving dr8u8nks home at night. I don't see how Tesla is

nfrequent

nfrequent 14 minutes ago

Get ready. Phase One complete!!!
https://archive.fast-edgar.com/20241217/AP2Z522CZZ2R52V222JG2WY2CDQEZZ226L62/

XMaster2023

XMaster2023 15 minutes ago

Well now kinda sensitive. We can only talk about others tracking the approval one time because it doesn’t meet your short agenda? Funny how an American Society are tracking approval in the UK. They understand the approval will have a big impact on the gene therapy world. Your tacid comments will

Lumen Technologies

FTSE Eurofirst 100

Pet Center Comercio E Pa... ON

Core Metropolis Fundo de...

Bayerische Motoren Werke

Western Asset Investment...

INTESA SANPAOLO

Intesa Sanpaolo

Intesa Sanpaolo

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions